Evaluation of Blood Pressure Medication Use Associated with Cyclosporine-Induced Hypertension in the Allogeneic Bone Marrow Transplant Population

s / Biol Blood Marrow Transplant 19 (2013) S370eS380 S375 Siro, respectively, after Feb 2010. ITT CI of aGVHD was 0.32 (95% CI: 0.21, 0.43) and 0.46 (95% CI: 0.37, 0.54) prior to and after Feb 2010, respectively (P1⁄4 .11). Eighty-six patients (44%) were considered at high risk for IFI pre-HSCT by standard criteria. The rate of IFI post HCT was 9/69 (13%) and 18/127 (14%) prior to and after Feb 2010, respectively. Proven (n1⁄42) or probable (n1⁄42) IFI was only observed in 4 patients (2%), with the remainder having possible IFI. Subgroup analysis did not find any statistical difference between the two groups for aGVHD analyzed by stem cell source or IFI analyzed by pre-HSCT risk. In addition, there was no difference in the number of dose modifications required and when patients were analyzed by actual day of azole start. Conclusion: Delaying the start of triazole prophylaxis till 7 days after allo-HSCT does not affect outcomes, including achieving and maintaining therapeutic levels of GVHD prophylaxis, and incidence of aGVHD or IFI.